Overview

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

Oct 23, 2020

Read Press Release

ACR Convergence 2020

November 5 - November 9, 2020

Q2 2020

Quarterly Results

Jun 30, 2020

PDF HTML

Earnings Release

AUDIO

Webcast

PDF

Conference Call Transcript

PDF HTML

10-Q

PDF HTML

10-Q/A

HTML

Financials

ZIP XLS HTML

XBRL

Symbol

Nasdaq: CRBP

Price

Change

MKT Cap

Volume

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

Yuval Cohen, Ph.D.

Chief Executive Officer, Director

Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus View Full Bio

Craig Millian, MBA

Chief Commercial Officer

Craig Millian joined Corbus as Chief Commercial Officer in February 2019. Mr. Millian brings 25 years of experience leading commercial organizations for a range of pharmaceutical companies as well as a successful track record building View Full Bio

Sean Moran, CPA, MBA

Chief Financial Officer

Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery, and medical device companies. Mr. Moran has successfully managed operations from start View Full Bio

Barbara White, M.D.

Chief Medical Officer and Head of Research

Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and View Full Bio

Robert Discordia, Ph.D.

Chief Operating Officer

Robert Discordia, Ph.D., joined Corbus in May 2018. Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and business operations. Prior to joining the Company, Dr. Discordia was View Full Bio

Ross Lobell

Vice President, Regulatory Affairs

Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory View Full Bio

Alan Holmer

Chairman of the Board

Alan F. Holmer served from 1996 to 2005 as President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the worldwide interests of leading pharmaceutical and View Full Bio

Avery W. Catlin

Director

Avery W. Catlin previously served as Senior Vice President, Chief Financial Officer, and Secretary of Celldex Therapeutics, Inc., a public biopharmaceutical company. Prior to joining Celldex Therapeutics, Inc. in January 2000, he served as View Full Bio

Yuval Cohen, Ph.D.

Chief Executive Officer, Director

Rachelle Jacques

Director

Ms. Jacques is the Chief Executive Officer of Enzyvant Therapeutics, Inc, a private biopharmaceutical company focused on developing therapies for patients with rare diseases. Previously, beginning in 2017, she served as the Senior Vice View Full Bio

John Jenkins, M.D.

Director

Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency View Full Bio

Pete Salzmann, M.D., MBA

Director

Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member View Full Bio

Latest News

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

Upcoming Event

ACR Convergence 2020

Latest Financial Results

Q2 2020

Stock Information

Symbol

Price

Change

MKT Cap

Volume

Company Overview

Officers & Directors

Yuval Cohen, Ph.D.

Craig Millian, MBA

Sean Moran, CPA, MBA

Barbara White, M.D.

Robert Discordia, Ph.D.

Ross Lobell

Alan Holmer

Avery W. Catlin

Yuval Cohen, Ph.D.

Rachelle Jacques

John Jenkins, M.D.

Pete Salzmann, M.D., MBA

Overview

Latest News

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

Upcoming Event

ACR Convergence 2020

Latest Financial Results

Q2 2020

Stock Information

Symbol

Price

Change

MKT Cap

Volume

Company Overview

Sign up for email alerts

Officers & Directors

Yuval Cohen, Ph.D.

Craig Millian, MBA

Sean Moran, CPA, MBA

Barbara White, M.D.

Robert Discordia, Ph.D.

Ross Lobell

Alan Holmer

Avery W. Catlin

Yuval Cohen, Ph.D.

Rachelle Jacques

John Jenkins, M.D.

Pete Salzmann, M.D., MBA